News | May 29, 2021
SMS Pharmaceuticals posts Q4FY21 consolidated PAT of Rs. 22.21 Cr
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
The product patent has been already filed under fast track approval
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Subscribe To Our Newsletter & Stay Updated
